Abstract
A total of 458 eligible patients, from 21 centres, with histologically or cytologically confirmed SCLC were allocated at random to three chemotherapy regimens, each given at 3-week intervals. In two regimens, etoposide, cyclophosphamide, methotrexate and vincristine were given for a total of either three courses (ECMV3) or six courses (ECMV6). In the third regimen, etoposide and ifosfamide were given for six courses (EI6). Patients with limited disease (56% of the total) also received radiotherapy to the primary site after the third course of chemotherapy in all three groups. A partial response occurred in 45% of 144 ECMV3 patients, 48% of 141 ECMV6, and 53% of 141 EI6 patients assessed, and a complete response in a further 15%, 9%, and 13% respectively, giving total response rates of 60%, 57%, and 67%, respectively. There was no overall survival advantage to any of the three regimens. At 1 year, 24%, 29%, and 30% of patients were alive, and at 2 years 7%, 8%, and 9%, respectively. The median survival time was 7.4 months in the ECMV3 group, 8.6 months in the ECMV6 group and 8.8 months in the EI6 group. The individual factors: poor performance status, extensive disease, the presence of dysphagia and a raised white blood cell count on admission adversely affected prognosis. The results do not exclude the possibility of a minor survival advantage with the two 6-course regimens. The findings on quality of life are presented in the companion paper (MRC Lung Cancer Working Party, 1993b).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cullen M., Morgan D., Gregory W., Robinson M., Cox D., McGivern D., Ward M., Richards M., Stableforth D., Macfarlane A. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol. 1986;17(2):157–160. doi: 10.1007/BF00306746. [DOI] [PubMed] [Google Scholar]
- Giaccone G., Dalesio O., McVie G. J., Kirkpatrick A., Postmus P. E., Burghouts J. T., Bakker W., Koolen M. G., Vendrik C. P., Roozendaal K. J. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1993 Jul;11(7):1230–1240. doi: 10.1200/JCO.1993.11.7.1230. [DOI] [PubMed] [Google Scholar]
- Hansen H. H. Management of small-cell cancer of the lung. Lancet. 1992 Apr 4;339(8797):846–849. doi: 10.1016/0140-6736(92)90287-d. [DOI] [PubMed] [Google Scholar]
- Morittu L., Earl H. M., Souhami R. L., Ash C. M., Tobias J. S., Geddes D. M., Harper P. G., Spiro S. G. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer. 1989 May;59(5):801–804. doi: 10.1038/bjc.1989.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rawson N. S., Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990 Apr;61(4):597–604. doi: 10.1038/bjc.1990.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spiro S. G., Souhami R. L. Duration of chemotherapy in small cell lung cancer. Thorax. 1990 Jan;45(1):1–2. doi: 10.1136/thx.45.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spiro S. G., Souhami R. L., Geddes D. M., Ash C. M., Quinn H., Harper P. G., Tobias J. S., Partridge M., Eraut D. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989 Apr;59(4):578–583. doi: 10.1038/bjc.1989.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thatcher N., Cerny T., Stout R., Anderson H., Barber P. V., Wolstenholme R. J., Barnes P., Deiraniya A. Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer. 1987 Nov 15;60(10):2382–2387. doi: 10.1002/1097-0142(19871115)60:10<2382::aid-cncr2820601006>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]